Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.31 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.31 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.31 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL436640 | 0.82 | CA12 (0.34) | KMT2AMEN1MAPTGAAALDH1A1 | |
| SCHEMBL434179 | 0.71 | SMN1; SMN2 (0.47) | SMN1; SMN2KMT2AMEN1MAPTGAA | |
| SCHEMBL434818 | 0.70 | KDM4E (0.35) | SMN1; SMN2KMT2AMEN1MAPTGAA | |
| SCHEMBL8135381 | 0.67 | SMN1; SMN2 (0.49) | SMN1; SMN2KMT2AMEN1MAPTGAA | |
| SCHEMBL1918262 | 0.66 | SMN1; SMN2 (0.47) | SMN1; SMN2KMT2AMEN1MAPTGAA | |
| SCHEMBL27918038 | 0.64 | ALDH1A1 (0.35) | SMN1; SMN2KMT2AMEN1MAPTGAA | |
| SCHEMBL5310060 | 0.64 | KMT2A (0.47) | SMN1; SMN2KMT2AMEN1MAPTGAA | |
| SCHEMBL7228617 | 0.64 | ALDH1A1 (0.43) | SMN1; SMN2KMT2AMAPTGAAPOLB | |
| SCHEMBL27933553 | 0.63 | APP (0.44) | KMT2AMEN1MAPTGAAPOLB | |
| SCHEMBL9099498 | 0.63 | ERN1 (0.49) | SMN1; SMN2KMT2AMEN1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9839623-B2 | Tricyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-9839623-B2 | Tricyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-9839623-B2 | Tricyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20160354338-A1 | TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160354338-A1 | TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160354338-A1 | TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-9266896-B2 | Tricyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| EP-2595988-B1 | TRICYCLIC COMPOUNDS AND METHDS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2014-12-17 | — | — | EP | disclosed |
| EP-2595988-B1 | TRICYCLIC COMPOUNDS AND METHDS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2014-12-17 | — | — | EP | disclosed |
| CN-103249735-A | Tricyclic compounds and methods of making and using the same | ZAFGEN CORP | 2013-08-14 | — | — | CN | disclosed |
| EP-2595988-A1 | TRICYCLIC COMPOUNDS AND METHDS OF MAKING AND USING SAME | Zafgen, Inc. (US) | 2013-05-29 | — | — | EP | disclosed |
| US-20130123235-A1 | Tricyclic Compounds and Methods of Making and Using Same | ZAFGEN, INC. | 2013-05-16 | — | — | US | disclosed |
| US-20130123235-A1 | Tricyclic Compounds and Methods of Making and Using Same | ZAFGEN, INC. | 2013-05-16 | — | — | US | disclosed |
| US-20130123235-A1 | Tricyclic Compounds and Methods of Making and Using Same | ZAFGEN, INC. | 2013-05-16 | — | — | US | disclosed |
| WO-2012012642-A1 | TRICYCLIC COMPOUNDS AND METHDS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012012642-A1 | TRICYCLIC COMPOUNDS AND METHDS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123235-A1 | Tricyclic Compounds and Methods of Making and Using Same | CES2, DNPEP, METAP2 | SMN1; SMN2 3667/4885KMT2A 916/4885MEN1 1228/4885 |
| US-20160354338-A1 | TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | CES2, DNPEP, METAP2 | SMN1; SMN2 3667/4885KMT2A 916/4885MEN1 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.